The U.S. Food and Drug Administration gave the green light to Johnson & Johnson’s Janssen for Erleada (apalutamide) as a treatment for metastatic castration-sensitive prostate cancer.
Lexicon Pharmaceuticals Inc. said France’s Sanofi SA will pay the Texas-based drugmaker $260 million for the termination of their partnership to develop the diabetes drug Zynquista.
Idera Pharmaceuticals announced an immuno-oncology collaboration with AbbVie to evaluate a combination therapy aimed at stimulating the immune system to create an anti-tumor response.
AbbVie’s Rinvoq was approved by the FDA for treating adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.
Sarepta Therapeutics Inc. was informed that an adverse event report was erroneously submitted to the U.S. health regulator regarding an ongoing study of the company’s gene therapy for Duchenne muscular dystrophy (DMD).
Rockville, Maryland-based RegenxBio entered a license deal with Pfizer for a gene therapy for Friedreich’s ataxia, the most common hereditary ataxia.
The U.S. Food and Drug Administration approved Celgene Corp.’s Otezla (apremilast) 30 mg twice daily for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical teamed up to study the most common type of metastatic colorectal cancer.
Gilead Sciences announced that a path forward was established to submit a New Drug Application in 2019 for the investigational oral, selective JAK1 inhibitor filgotinib as a rheumatoid arthritis treatment.
Rare Cancer Treatments and the Power of Checkpoint Inhibitors Among Hot Topics at ASCO
American Society of Clinical Oncology (ASCO), Blockbusters, Cancer, Checkpoint Inhibitors, Clinical Studies, Clinical Trials, Data, Desmoid Tumors, Endocrine Therapy, Gastroenteropancreatic neuroendocrine tumors, Lung Cancer, Nobel Prize, Nobel Prize in Physiology or Medicine, Orphan Diseases, PD-L1 Inhibitor, PD-L1 protein, PIK3CA mutations, R&D, Rare Cancers, Rare Sarcomas, Tenosynovial Giant Cell Tumor (TGCT)With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.
